Perspective Therapeutics and PMV Pharma Provide Clinical Trial Updates
• Perspective Therapeutics' VMT-α-NET program shows promising early results in neuroendocrine tumors, with no dose-limiting toxicities observed in Phase 1/2a trials.
• Perspective Therapeutics plans to initiate therapeutic dosing of PSV359, a FAP-α-targeted radiopharmaceutical, with potential study enrollment around mid-2025.
• PMV Pharmaceuticals' rezatapopt Phase 2 trial for TP53 Y220C-mutated solid tumors is on track, with an interim analysis expected by mid-2025.
• PMV Pharmaceuticals is collaborating with Foundation Medicine to develop a companion diagnostic for rezatapopt, a p53 Y220C reactivator.
Innovent's Taletrectinib (DOVBLERON®) Receives Expanded Approval in China for ROS1-Positive NSCLC
• China's NMPA has approved Innovent's taletrectinib for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).
• The approval was based on positive outcomes from the Phase II TRUST-I trial, which showed high and durable overall responses.
• In TKI-naïve patients, taletrectinib achieved a confirmed objective response rate of 91% and intracranial cORR of 88%.
• Taletrectinib is now approved for both first-line and previously treated ROS1-positive NSCLC patients in China.
© Copyright 2025. All Rights Reserved by MedPath